



## ASXL3-Related Disorder

Synonym: Bainbridge-Ropers Syndrome (BRPS)

Meena Balasubramanian, MBBS, DCH, FRCPCH, MD<sup>1</sup> and Schaida Schirwani, MBChB, MSc, MRCP<sup>2</sup>

Created: November 5, 2020.

## Summary

### Clinical characteristics

ASXL3-related disorder is characterized by developmental delay or intellectual disability, typically in the moderate to severe range, with speech and language delay and/or absent speech. Affected individuals may also display autistic features. There may be issues with feeding. While dysmorphic facial features have been described, they are typically nonspecific. Affected individuals may also have hypotonia that can transition to spasticity resulting in unusual posture with flexion contractions of the elbows, wrists, and fingers. Other findings may include poor postnatal growth, strabismus, seizures, sleep disturbance, and dental anomalies.

### Diagnosis/testing

The diagnosis of ASXL3-related disorder is established in a proband by identification of a heterozygous pathogenic variant in ASXL3 by molecular genetic testing.

### Management

*Treatment of manifestations:* Feeding therapy; gastrostomy tube placement for those with persistent feeding issues; anti-reflux medication and/or fundoplication for those with gastroesophageal disease; standard treatment for epilepsy, joint contractures, sleep apnea, dental anomalies, strabismus and/or refractive error, and developmental delay / intellectual disability.

*Surveillance:* At each visit: Measurement of growth parameters and nutritional status; assessment of developmental progress, behavioral issues, new neurologic manifestations (change in tone, seizure onset and/or frequency), mobility and self-help skills, as well as signs and symptoms of sleep disturbance. Dental evaluation every six months after age three years or as clinically indicated. At least annual ophthalmology evaluation.

**Author Affiliations:** 1 Sheffield Children's NHS Foundation Trust, University of Sheffield, Sheffield, United Kingdom; Email: meena.balasubramanian@nhs.net. 2 Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom; Email: schaida.schirwani@nhs.net.

## Genetic counseling

*ASXL3*-related disorder is an autosomal dominant disorder typically caused by a *de novo* pathogenic variant. Rarely, individuals diagnosed with *ASXL3*-related disorder have the disorder as the result of a pathogenic variant inherited from a parent. If the *ASXL3* pathogenic variant identified in the proband is not identified in either parent, the risk to sibs is presumed to be low but greater than that of the general population because of the possibility of parental germline mosaicism. Once the *ASXL3* pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.

## Diagnosis

Formal clinical diagnostic criteria for *ASXL3*-related disorder have not been established.

## Suggestive Findings

*ASXL*-related disorder **should be considered** in individuals with the following clinical findings:

- Developmental delay (DD) or intellectual disability, typically in the moderate to severe range; AND
- Any of the following features presenting in infancy or childhood:
  - Speech and language delay and/or absent speech
  - Autism spectrum disorder or autistic traits
  - Dysmorphic facial features including prominent forehead; highly arched eyebrows; synophrys, widely spaced eyes; downslanted palpebral fissures; long, tubular nose with prominent nasal bridge; wide mouth with full, everted vermilion of the lower lip; and crowded teeth
  - Feeding difficulties
  - Hypotonia
  - Poor postnatal growth
  - Epilepsy including generalized tonic-clonic seizures and absence seizures
  - Vision impairment including strabismus
  - Skeletal findings such as Marfanoid habitus, pectus excavatum, scoliosis, arachnodactyly, and joint flexion with contractures

## Establishing the Diagnosis

The diagnosis of *ASXL3*-related disorder **is established** in a proband by identification of a heterozygous pathogenic (or likely pathogenic) variant in *ASXL3* by molecular genetic testing (see Table 1).

Note: (1) Per ACMG variant interpretation guidelines, the terms "pathogenic variants" and "likely pathogenic variants" are synonymous in a clinical setting, meaning that both are considered diagnostic and both can be used for clinical decision making. Reference to "pathogenic variants" in this section is understood to include any likely pathogenic variants. (2) Identification of a heterozygous *ASXL3* variant of uncertain significance does not establish or rule out a diagnosis of *ASXL3*-related disorder.

**Molecular genetic testing** in a child with developmental delay or an older individual with intellectual disability typically begins with chromosomal microarray analysis (CMA). If CMA is not diagnostic, the next step is typically either a multigene panel or exome sequencing. Note: Single-gene testing (sequence analysis of *ASXL3*, followed by gene-targeted deletion/duplication analysis) is rarely useful due to the nonspecific nature of clinical presentation and typically NOT recommended.

**Chromosomal microarray analysis (CMA)** uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including *ASXL3*) that cannot be detected by sequence analysis.

**An intellectual disability multigene panel** that includes *ASXL3* and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition in a person with a nondiagnostic CMA while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click [here](#). More detailed information for clinicians ordering genetic tests can be found [here](#)

**Comprehensive genomic testing** does not require the clinician to determine which gene(s) are likely involved. **Exome sequencing** is most commonly used, but **genome sequencing** may be performed, and yields results similar to an ID multigene panel with the additional advantage that exome and genome sequencing includes genes recently identified as causing ID, whereas some multigene panels may not.

For an introduction to comprehensive genomic testing click [here](#). More detailed information for clinicians ordering genomic testing can be found [here](#).

**Table 1.** Molecular Genetic Testing Used in *ASXL3*-Related Disorder

Gene <sup>1</sup>	Method	Proportion of Probands with a Pathogenic Variant <sup>2</sup> Detectable by Method
<i>ASXL3</i>	Sequence analysis <sup>3</sup>	98%-99% <sup>4, 5</sup>
	Gene-targeted deletion/duplication analysis <sup>6</sup>	1%-2% <sup>7</sup>
	CMA <sup>8</sup>	Rare <sup>7</sup>

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on allelic variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click [here](#).

4. From Balasubramanian et al [2017], Kuechler et al [2017], and data derived from the subscription-based professional view of Human Gene Mutation Database [Stenson et al 2020]

5. Most individuals so far reported with *ASXL3*-related disorder have truncating or splice site variants in *ASXL3*.

6. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

7. At least two individuals in a cohort with typical *ASXL3*-related disorder have *ASXL3* deletions identified on chromosomal microarray (CMA) [Authors, personal observation]. Both individuals had deletions that included only *ASXL3* without deletion of adjacent genes.

8. Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including *ASXL3*) that cannot be detected by sequence analysis. The ability to determine the size of the deletion/duplication depends on the type of microarray used and the density of probes in the 18q12.1 region. CMA designs in current clinical use target the 18q12.1 region.

## Clinical Characteristics

### Clinical Description

To date, 44 individuals from 40 families have been identified with a pathogenic variant in *ASXL3* [Bainbridge et al 2013, Dinwiddie et al 2013, Hori et al 2016, Retterer et al 2016, Srivastava et al 2016, Balasubramanian et al

2017, Chinen et al 2017, Dad et al 2017, Kuechler et al 2017, Bacrot et al 2018, Contreras-Capetillo et al 2018, Koboldt et al 2018, Myers et al 2018a, Myers et al 2018b, Verhoeven et al 2018, Zhang et al 2018, Qiao et al 2019, Wayhelova et al 2019, Schirwani et al 2020]. The authors have collected clinical and molecular data on another 45 affected individuals in an additional cohort study that will be submitted for publication. The following description of the phenotypic features associated with this condition is based on these published reports and the additional cohort study (n=89 affected individuals).

**Table 2.** Select Features of *ASXL3*-Related Disorder

Feature	% of Persons w/Feature	Comment
Speech delay	100%	Most are nonverbal or have very limited speech.
Intellectual disability	99%	Typically moderate to severe
Facial dysmorphism	98%	See Suggestive Findings.
Hypotonia	86%	Central hypotonia can be assoc w/↑ tone in upper & lower limbs.
Behavioral concerns	78%	Incl autistic traits or an ASD diagnosis
Feeding difficulties	78%	Most patients in the early stages are referred w/feeding difficulties & failure to thrive.
Skeletal findings	74%	
Eyes	~50%	Strabismus is the most common finding.
Seizures	38%	GTCS & absence seizures; most have normal brain MRI imaging.

ASD = autism spectrum disorder; GTCS = generalized tonic-clonic seizures

**Speech delay.** All individuals with *ASXL3*-related disorder have delayed speech and language development. First word was achieved in 32% of affected individuals, at an average age of 28.8 months [Authors, personal observation].

- A majority of known individuals with *ASXL3*-related disorder are nonverbal. Use of communication devices with expert speech and language therapy input can often be helpful in these individuals to develop alternate modes of communication, as it appears that receptive language skills may be better than expressive language skills in persons with this disorder.
- Less commonly, communication through gesture, sounds, words, and sentences has been described.

**Intellectual disability (ID).** A majority of the individuals with *ASXL3*-related disorder have developmental delay and intellectual disability that is generally moderate to severe. However, a spectrum of intellectual capabilities has been described.

- Initial reports were of affected individuals with profound ID partly attributed to ascertainment bias; however, as more affected individuals have been identified, milder degrees of ID are being observed.
- The authors are aware of a father and son with a paternally inherited truncating *ASXL3* pathogenic variant, suggesting that a few individuals with *ASXL3*-related disorder may have normal cognition [Authors, personal observation].

Children with *ASXL3*-related disorder may be able to attend a mainstream school with dedicated support. However, so far, most individuals have required special educational provisions. The vast majority of adults described to date have required assisted living with some degree of independence.

**Dysmorphic features.** Individuals with *ASXL3*-related disorder have similar but typically nonspecific facial features (see Suggestive Findings) which are often recognized only after a diagnosis has been established.

**Behavioral concerns.** More than three-quarters of individuals with *ASXL3*-related disorder have significant behavioral, social, and communication difficulties with substantial impact on the affected individuals and their families.

- About half of affected individuals meet the formal clinical diagnostic criteria of an autism spectrum disorder (ASD), whereas others have autistic-like features. However, others are described as having a very friendly, placid personality.
- Other (more rarely) associated behaviors can include:
  - Hand flapping
  - Agitation
  - Motor and/or vocal tics (Tourette syndrome)
  - Hyperventilation episodes
  - Teeth grinding (bruxism)
  - Attention-deficit disorder (ADD)
  - Pica
  - Self-harm behaviors including self-biting, face scratching, and head bangingOnset of self-injurious behavior can be as early as age two years; some individuals display this behavior later in life.

**Growth.** Most affected individuals display normal birth weight for gestational age but often experience poor postnatal growth as a result of feeding issues during infancy. During this time, growth may decline to 2 SD below the mean or more for age. Short stature is not a primary feature of *ASXL3*-related disorder and growth (both weight and length/height) typically stabilize or normalize after appropriate treatment of feeding issues (see following).

**Feeding issues.** Most individuals with *ASXL3*-related disorder, especially in the younger age groups, come to medical attention because of poor postnatal growth (see above) and ongoing feeding difficulties. They may display poor suck and swallow, recurrent vomiting, and gastroesophageal reflux disease.

- Swallow studies have shown impairment of oral stage of swallowing and oral sensorimotor feeding delay characterized by oral motor weakness, reduced mastication skills for age, and suspected oral hypersensitivity. This may result in delay in weaning and food refusal behavior. Affected individuals may also have a high arched palate.
- The severity of feeding difficulties varies considerably, with some affected children requiring long-term gastrostomy tube insertion while in others, feeding may be improved with the use of slow-flow nipples (see Treatment of Manifestations).
- Although initial feeding issues may resolve with age, there may be ongoing difficulties with feeding as a result of food aversion, sensitivity to different food textures, and behavioral issues that may affect eating.

### Neurologic

- **Hypotonia** is a common feature in individuals with *ASXL3*-related disorder, especially during the neonatal period and in early infancy. Later in life, some children develop an unusual posture and contractures with elbow, wrist, and fingers held in the flexion position. This is likely because of spasticity that becomes apparent with age.

- **Seizures** occur in about one third of affected individuals and can range from generalized tonic-clonic seizures to absence seizures. Seizures typically respond to standard anti-seizure medications.
- **Imaging.** Most individuals with *ASXL3*-related disorder have normal brain imaging and do not have any characteristic brain findings.

**Skeletal features.** More than two thirds of individuals with *ASXL3*-related disorder have a skeletal abnormality. Findings may include:

- Marfanoid habitus
- Pectus excavatum
- Joint hypermobility
- Pes planus
- Digital abnormalities including arachnodactyly, syndactyly, clinodactyly, contractures, and tapering fingers
- Postural scoliosis (possibly due to hypotonia)
- Delayed bone age

**Sleep.** Sleep disturbance is a common finding, with some affected individuals reported to have sleep apnea, for which a sleep study and further evaluation to establish a cause is warranted. Some affected individuals have abnormal breathing patterns including apnea, breath-holding episodes, and irregular breathing patterns (particularly at night) that coincide with sleep disturbances.

**Eyes.** Strabismus has been described in more than half of affected individuals. It can be persistent or intermittent. Some affected individuals have myopia, hyperopia, and ptosis. Visual difficulties (including astigmatism) needing correction may also be seen.

**Dental.** Dental abnormalities, ranging from dental overcrowding, malocclusion, and large teeth to severe hypodontia, are present in nearly 50% of individuals.

#### **Other**

- Some affected individuals have problems with temperature regulation and are insensitive to cold/heat.
- Altered pain perception has been described in association with this condition but is not a consistent finding.

## **Genotype-Phenotype Correlations**

No genotype-phenotype correlations for *ASXL3* have been identified.

## **Nomenclature**

*ASXL3*-related disorder was first described by Bainbridge et al [2013] in four unrelated individuals with truncating variants in *ASXL3*; it is sometimes referred to as Bainbridge-Ropers syndrome.

## **Prevalence**

The prevalence of *ASXL3*-related disorder is not known. However, to date *ASXL3* is one of the top ten genes in which pathogenic variants have been found in large-scale exome sequencing studies of individuals with ID [Fitzgerald et al 2015, Wright et al 2015].

Affected individuals have been reported from all ethnicities and most have been identified in countries that undertake genomic testing in individuals with ID.

## Genetically Related (Allelic) Disorders

All heterozygous pathogenic variants so far reported in association with *ASXL3*-related disorder have been truncating and splicing variants; missense variants are not thought to be causative. However, biallelic missense *ASXL3* variants have been reported in four individuals with congenital heart defects (tetralogy of Fallot or transposition of the great arteries) from two families [Fu et al 2021]; further evidence is required to establish the role of biallelic missense *ASXL3* variants in the pathogenesis of congenital heart defects.

Sporadic tumors (including parathyroid adenomas and prostate and pancreatic cancers) occurring as single tumors in the absence of any other findings of *ASXL3*-related disorder may harbor somatic variants in *ASXL3* that are **not** present in the germline. In these circumstances predisposition to these tumors is not heritable. For more information see Cancer and Benign Tumors.

## Differential Diagnosis

Because the clinical presentation of *ASXL3*-related disorder is typically nonspecific global developmental delay, all disorders associated with intellectual disability without other distinctive findings should be considered in the differential diagnosis. See [OMIM Autosomal Dominant, Autosomal Recessive, Nonsyndromic X-Linked, and Syndromic X-Linked Intellectual Developmental Disorder Phenotypic Series](#).

Note: Heterozygous pathogenic variants *ASXL1* and *ASXL2*, the other two genes in the ASXL gene family (see Molecular Pathogenesis), are associated with [Bohring-Opitz syndrome \(BOS\)](#) and Shashi-Pena syndrome, respectively. Both disorders are characterized by developmental delay but can be distinguished from *ASXL3*-related disorder by the characteristic facial dysmorphism associated with BOS, and by macrocephaly and abnormal brain imaging in Shashi-Pena syndrome.

## Management

Consensus clinical management guidelines for *ASXL3*-related disorder have not been published.

## Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with *ASXL3*-related disorder, the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

**Table 3.** Recommended Evaluations Following Initial Diagnosis in Individuals with *ASXL3*-Related Disorder

System/Concern	Evaluation	Comment
<b>Development</b>	Developmental assessment	To incl motor, adaptive, cognitive, & speech/language eval
		Eval for early intervention / special education
<b>Psychiatric/ Behavioral</b>	Neuropsychiatric eval	For persons age >12 mos: screen for behavior concerns incl sleep disturbances, ADD, &/or traits suggestive of ASD.
<b>Constitutional</b>	Measurement of growth parameters	To evaluate for growth deficiency
<b>Gastrointestinal/ Feeding</b>	Gastroenterology / nutrition / feeding team eval	To incl eval of aspiration risk, GERD, & nutritional status
		Consider eval for gastric tube placement in those w/dysphagia &/or aspiration risk.



Table 3. continued from previous page.

System/Concern	Evaluation	Comment
<b>Neurologic</b>	Neurologic eval	<ul style="list-style-type: none"> <li>To incl brain MRI</li> <li>Consider EEG if seizures are a concern.</li> </ul>
<b>Musculoskeletal</b>	Orthopedics / physical medicine & rehab / PT & OT eval	<p>To incl assessment of:</p> <ul style="list-style-type: none"> <li>Gross motor &amp; fine motor skills</li> <li>Contractures, pes planus, scoliosis &amp; joint hypermobility</li> <li>Mobility, activities of daily living, &amp; need for adaptive devices</li> <li>Need for PT (to improve gross motor skills) &amp;/or OT (to improve fine motor skills)</li> </ul>
<b>Respiratory</b>	Assessment for sleep disturbance &/or evidence of sleep apnea	
<b>Dental</b>	Age-appropriate dental eval	To assess for malocclusion & hypodontia
<b>Eyes</b>	Ophthalmologic eval	To assess for strabismus & ↓ vision
<b>Miscellaneous/ Other</b>	Consultation w/clinical geneticist &/or genetic counselor	To incl genetic counseling
	Family support/resources	<p>Assess need for:</p> <ul style="list-style-type: none"> <li>Community or online resources such as <a href="#">Parent to Parent</a>;</li> <li>Social work involvement for parental support;</li> <li>Home nursing referral.</li> </ul>

ADD = attention-deficit disorder; ASD = autism spectrum disorder; GERD = gastroesophageal reflux disease; OT = occupational therapy; PT = physical therapy

## Treatment of Manifestations

Table 4. Treatment of Manifestations in Individuals with ASXL3-Related Disorder

Manifestation/ Concern	Treatment	Considerations/Other
<b>DD/ID</b>	See Developmental Delay / Intellectual Disability Management Issues.	
<b>Poor weight gain / Failure to thrive</b>	Feeding therapy; gastrostomy tube placement may be required for persistent feeding issues.	Low threshold for clinical feeding eval &/or radiographic swallowing study if clinical signs or symptoms of dysphagia
<b>GERD</b>	Anti-reflux medication; fundoplication or percutaneous endoscopic gastrostomy in severe situations	Consider consultation w/gastroenterology specialist in those w/severe disease.
<b>Epilepsy</b>	Standardized treatment w/ASM by experienced neurologist	<ul style="list-style-type: none"> <li>Many ASMs may be effective; none has been demonstrated effective specifically for this disorder.</li> <li>Education of parents/caregivers <sup>1</sup></li> </ul>
<b>Pes planus, joint contractures, scoliosis</b>	Standard treatment per orthopedist	
<b>Sleep apnea</b>	Standard treatment per ENT / sleep specialist	



Table 4. continued from previous page.

Manifestation/ Concern	Treatment	Considerations/Other
<b>Malocclusion &amp;/or hypodontia</b>	Standard treatment per dentist/orthodontist	
<b>Strabismus &amp;/or refractive error</b>	Standard treatment per ophthalmologist	
<b>Family/ Community</b>	<ul style="list-style-type: none"> <li>• Ensure appropriate social work involvement to connect families w/local resources, respite, &amp; support.</li> <li>• Coordinate care to manage multiple subspecialty appointments, equipment, medications, &amp; supplies.</li> </ul>	<ul style="list-style-type: none"> <li>• Ongoing assessment of need for palliative care involvement &amp;/or home nursing</li> <li>• Consider involvement in adaptive sports or Special Olympics.</li> </ul>

ASM = anti-seizure medication; DD = developmental delay; GERD = gastroesophageal reflux disease; ID = intellectual disability; OT = occupational therapy; PT = physical therapy

1. Education of parents/caregivers regarding common seizure presentations is appropriate. For information on non-medical interventions and coping strategies for children diagnosed with epilepsy, see [Epilepsy Foundation Toolbox](#).

## Developmental Delay / Intellectual Disability Management Issues

The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.

**Ages 0-3 years.** Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs.

**Ages 3-5 years.** In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based; for children too medically unstable to attend, home-based services are provided.

**All ages.** Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of life. Some issues to consider:

- IEP services:
  - An IEP provides specially designed instruction and related services to children who qualify.
  - IEP services will be reviewed annually to determine whether any changes are needed.
  - Special education law requires that children participating in an IEP be in the least restrictive environment feasible at school and included in general education as much as possible, when and where appropriate.
  - Vision consultants should be a part of the child's IEP team to support access to academic material.
  - PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the affected individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.
  - As a child enters the teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.

- A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.
- Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a US public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
- Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.

## Motor Dysfunction

### Gross motor dysfunction

- Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, and hip dislocation).
- Consider use of durable medical equipment and positioning devices as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, and adaptive strollers).
- For muscle tone abnormalities including hypertonia or dystonia, consider involving appropriate specialists to aid in management of baclofen, tizanidine, Botox<sup>®</sup>, anti-parkinsonian medications, or orthopedic procedures.

**Fine motor dysfunction.** Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and writing.

**Oral motor dysfunction** should be assessed at each visit and clinical feeding evaluations and/or radiographic swallowing studies should be obtained for choking/gagging during feeds, poor weight gain, frequent respiratory illnesses, or feeding refusal that is not otherwise explained. Assuming that the child is safe to eat by mouth, feeding therapy (typically from an occupational or speech therapist) is recommended to help improve coordination or sensory-related feeding issues. Feeds can be thickened or chilled for safety. When feeding dysfunction is severe, an NG-tube or G-tube may be necessary.

**Communication issues.** Consider evaluation for alternative means of communication (e.g., [augmentative and alternative communication](#) [AAC]) for individuals who have expressive language difficulties. An AAC evaluation can be completed by a speech-language pathologist who has expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication. AAC devices can range from low-tech, such as picture exchange communication, to high-tech, such as voice-generating devices. Contrary to popular belief, AAC devices do not hinder verbal development of speech, but rather support optimal speech and language development.

### Social/Behavioral Concerns

Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and typically performed one on one with a board-certified behavior analyst.

Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications, such as medication used to treat attention-deficit/hyperactivity disorder, when necessary.

Concerns about serious aggressive or destructive behavior can be addressed by a pediatric psychiatrist.

## Surveillance

**Table 5.** Recommended Surveillance for Individuals with ASXL3-Related Disorder

System/Concern	Evaluation	Frequency
<b>Development</b>	Monitor developmental progress & educational needs.	At each visit
<b>Psychiatric/ Behavioral</b>	Behavioral assessment for attention & aggressive or self-injurious behavior	
<b>Feeding</b>	<ul style="list-style-type: none"> <li>• Measurement of growth parameters</li> <li>• Eval of nutritional status &amp; signs/symptoms of GERD or feeding aversion</li> </ul>	
<b>Neurologic</b>	<ul style="list-style-type: none"> <li>• Monitor those w/seizures as clinically indicated.</li> <li>• Assess for new manifestations incl seizures &amp; changes in tone.</li> </ul>	
<b>Musculoskeletal</b>	Physical medicine, OT/PT assessment of mobility, self-help skills	
<b>Respiratory</b>	Assess for signs/symptoms of sleep disturbance & sleep apnea.	
<b>Miscellaneous/ Other</b>	Assess family need for social work support (e.g., palliative/respite care, home nursing, & other local resources) & care coordination.	
<b>Dental</b>	Eval by dentist	Every 6 mos after age 3 yrs or as clinically indicated
<b>Eyes</b>	Ophthalmology eval	Annually or as clinically indicated

GERD = gastroesophageal disease; OT = occupational therapy; PT = physical therapy

## Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

## Therapies Under Investigation

Search [ClinicalTrials.gov](https://clinicaltrials.gov) in the US and [EU Clinical Trials Register](https://clinicaltrialsregister.eu) in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

## Genetic Counseling

*Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.*

## Mode of Inheritance

ASXL3-related disorder is an autosomal dominant disorder typically caused by a *de novo* pathogenic variant.

### Parents of a proband

- To date, most individuals with ASXL3-related disorder whose parents have undergone molecular genetic testing have the disorder as a result of a *de novo* ASXL3 pathogenic variant.
- Rarely, individuals diagnosed with ASXL3-related disorder have the disorder as the result of a pathogenic variant inherited from a parent.

- Molecular genetic testing is recommended for the parents of a proband to confirm their genetic status and to allow reliable recurrence risk counseling.
- If the pathogenic variant identified in the proband is not identified in either parent, the following possibilities should be considered:
  - The proband has a *de novo* pathogenic variant. Note: A pathogenic variant is reported as "*de novo*" if: (1) the pathogenic variant found in the proband is not detected in parental DNA; and (2) parental identity testing has confirmed biological maternity and paternity. If parental identity testing is not performed, the variant is reported as "assumed *de novo*" [Richards et al 2015].
  - The proband inherited a pathogenic variant from a parent with germline (or somatic and germline) mosaicism. Sib recurrence due to presumed parental germline mosaicism has been reported in three families [Koboldt et al 2018, Schirwani et al 2020]. Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism.

**Sibs of a proband.** The risk to the sibs of the proband depends on the genetic status of the proband's parents:

- If a parent of the proband is heterozygous for the *ASXL3* pathogenic variant, the risk to the sibs of inheriting the variant is 50%.
- If the *ASXL3* pathogenic variant cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental germline mosaicism [Koboldt et al 2018, Schirwani et al 2020].

**Offspring of a proband.** Each child of an individual with *ASXL3*-related disorder has a 50% chance of inheriting the *ASXL3* pathogenic variant.

**Other family members.** The risk to other family members depends on the status of the proband's parents: if a parent has the *ASXL3* pathogenic variant, the parent's family members may be at risk.

## Related Genetic Counseling Issues

### Family planning

- The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to parents of affected individuals.

## Prenatal Testing and Preimplantation Genetic Testing

Once the *ASXL3* pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

## Resources

*GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).*

- **ASXL Rare Research Endowment (ARRE) Foundation**

**Email:** [info@arrefoundation.org](mailto:info@arrefoundation.org)

[arrefoundation.org/shashi-pena](http://arrefoundation.org/shashi-pena)

- **ASXL3 Mutations & Bainbridge-Ropers Syndrome**

[www.asxl3.com](http://www.asxl3.com)

- **Unique: The Rare Chromosome Disorder Support Group**

United Kingdom

**Phone:** 44(0)1883 723356

**Email:** [info@rarechromo.org](mailto:info@rarechromo.org)

[Bainbridge-Ropers syndrome](#)

- **Simons Searchlight Registry**

*Simons Searchlight aims to further the understanding of rare genetic neurodevelopmental disorders.*

**Phone:** 855-329-5638

**Fax:** 570-214-7327

**Email:** [coordinator@simonssearchlight.org](mailto:coordinator@simonssearchlight.org)

[simonssearchlight.org](http://simonssearchlight.org)

## Molecular Genetics

*Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.*

**Table A.** ASXL3-Related Disorder: Genes and Databases

Gene	Chromosome Locus	Protein	HGMD	ClinVar
ASXL3	18q12.1	Putative Polycomb group protein ASXL3	ASXL3	ASXL3

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click [here](#).

**Table B.** OMIM Entries for ASXL3-Related Disorder ([View All in OMIM](#))

615115	ASXL TRANSCRIPTIONAL REGULATOR 3; ASXL3
615485	BAINBRIDGE-ROPERS SYNDROME; BRPS

## Molecular Pathogenesis

ASXL1, ASXL2, and ASXL3 are human homologs of the Drosophila additional sex combs (asx) genes that encode putative polycomb proteins and are likely to act as histone methyltransferases in complexes with other proteins [Katoh 2015]. Polycomb group proteins are implicated in embryogenesis and carcinogenesis through transcriptional regulation of target genes; ASXL1 is thought to be one of the most frequently mutated genes in malignant myeloid diseases; ASXL is a scaffold protein interacting with methyltransferases and additional proteins of the epigenetic machinery [Fisher et al 2003, Duployez et al 2016].

Truncating pathogenic variants in ASXL1 have been reported in association with Bohring-Opitz syndrome (BOS), which has phenotypic overlap with ASXL3-related disorder [Hoischen et al 2011]. More recently, truncating variants in ASXL2 were reported in association with a newly recognizable clinical phenotype [Shashi et al 2016].

*ASXL3* is expressed in similar tissues to *ASXL1* including brain, spinal cord, kidney, liver, and bone marrow, but at a lower level [Sahtoe et al 2016]. The high correlation of expression patterns between *ASXL1* and *ASXL3* may account for some of the shared phenotypic features.

**Mechanism of disease causation.** Loss of function

## Cancer and Benign Tumors

Somatic missense variants in *ASXL3* have been identified in nonsyndromic parathyroid adenomas and may contribute to simplex (a single occurrence in a family) parathyroid tumorigenesis [Wei et al 2018]. Somatic truncating variants in *ASXL3* have been reported in pancreatic and prostate cancers [Micol & Abdel-Wahab 2016].

## Chapter Notes

### Author Notes

Dr Balasubramanian's web page: [mellanbycentre.org/meena-balasubramanian](http://mellanbycentre.org/meena-balasubramanian)

In the area of pediatric dysmorphology / genomic medicine, the author has led several studies focused on genotype-phenotype correlation in newly identified genes from next-generation sequencing studies such as the Deciphering Developmental Disorders study and has several first/senior author papers published in this area in large cohorts of individuals with new syndromal diagnoses. The author has published the largest cohort of people so far with *ASXL3*-related disorder and continued to gather phenotypic data on more than 70 individuals with *ASXL3*-related disorder. She has also written the Unique patient support group information leaflet on the condition along with Anna Pelling from Unique ([www.rarechromo.org](http://www.rarechromo.org)).

### Acknowledgments

We would like to thank all the families and their clinicians who have thus far contributed to ongoing *ASXL3* research.

### Revision History

- 5 November 2020 (ma) Review posted live
- 21 April 2020 (mb) Original submission

## References

### Literature Cited

- Bacrot S, Mechler C, Talhi N, Martin-Coignard D, Roth P, Michot C, Ichkou A, Alibeu O, Nitschke P, Thomas S, Vekemans M, Razavi F, Boutaud L, Attie-Bitach T. Whole exome sequencing diagnoses the first fetal case of Bainbridge-Ropers syndrome presenting as pontocerebellar hypoplasia type 1. *Birth Defects Res.* 2018;110:538–542. PubMed PMID: 29316359.
- Bainbridge MN, Hu H, Muzny DM, Musante L, Lupski JR, Graham BH, Chen W, Gripp KW, Jenny K, Wienker TF, Yang Y, Sutton VR, Gibbs RA, Ropers HH. De novo truncating mutations in *ASXL3* are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. *Genome Med.* 2013;5:11. PubMed PMID: 23383720.
- Balasubramanian M, Willoughby J, Fry AE, Weber A, Firth HV, Deshpande C, Berg JN, Chandler K, Metcalfe KA, Lam W, Pilz DT, Tomkins S. Delineating the phenotypic spectrum of Bainbridge-Ropers syndrome: 12



- new patients with de novo, heterozygous loss-of-function mutations in ASXL3 and review of published literature. *J Med Genet.* 2017;54:537–43. PubMed PMID: 28100473.
- Chinen Y, Nakamura S, Ganaha A, Hayashi S, Inazawa J, Yanagi K, Nakanishi K, Kaname T, Naritomi K. 2018. Mild prominence of the Sylvian fissure in a Bainbridge-Ropers syndrome patient with a novel frameshift variant in ASXL3. *Clin Case Rep.* 2017;6:330–6. PubMed PMID: 29445472.
- Contreras-Capetillo SN, Vilchis-Zapata ZH, Ribbon-Conde J, Pinto-Escalante D. Global developmental delay and postnatal microcephaly: Bainbridge-Ropers syndrome with a new mutation in ASXL3. *Neurologia.* 2018;33:484–6. PubMed PMID: 28431838.
- Dad R, Walker S, Scherer SW, Hassan MJ, Kang SY, Minassian BA. Hyperventilation-athetosis in ASXL3 deficiency (Bainbridge-Ropers) syndrome. *Neurol Genet.* 2017;3:e189. PubMed PMID: 28955728.
- Dinwiddie DL, Soden SE, Saunders CJ, Miller NA, Farrow EG, Smith LD, Kingsmore SF. De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies. *BMC Med Genomics.* 2013;6:32. PubMed PMID: 24044690.
- Duployez N, Micol JB, Boissel N, Petit A, Geffroy S, Bucci M, Lapillonne H, Renneville A, Leverger G, Ifrah N, Dombret H, Abdel-Wahab O, Jourdan E, Preudhomme C. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). *Leuk Lymphoma.* 2016;57:199–200. PubMed PMID: 25856206.
- Fisher CL, Berger J, Randazzo F, Brock HW. A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. *Gene.* 2003;306:115–26. PubMed PMID: 12657473.
- Fitzgerald TW, Gerety SS, Jones WD, van Kogelenberg M, King DA, McRae J, Morley KI, Parthiban V, Al-Turki S, Ambridge K, et al. Deciphering Developmental Disorders Study: Large-scale discovery of novel genetic causes of developmental disorders. *Nature.* 2015;519:223–8. PubMed PMID: 25533962.
- Fu F, Li R, Lei TY, Wang D, Yang X, Han J, Pan M, Zhen L, Li J, Li FT, Jing XY, Li DZ, Liao C. Compound heterozygous mutation of the ASXL3 gene causes autosomal recessive congenital heart disease. *Hum Genet.* 2021;140:333–48. PubMed PMID: 32696347.
- Hoischen A, Van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, De Vries P, Janssen I, Van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wieczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, De Vries BB. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. *Nat Genet.* 2011;43:729–31. PubMed PMID: 21706002.
- Hori I, Miya F, Ohashi K, Negishi Y, Hattori A, Ando N, Okamoto N, Kato M, Tsunoda T, Yamasaki M, Kanemura Y, Kosaki K, Saitoh S. Novel splicing mutation in the ASXL3 gene causing Bainbridge-Ropers syndrome. *Am J Med Genet A.* 2016;170:1863–7. PubMed PMID: 27075689.
- Katoh M. Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine. *Expert Rev Proteomics.* 2015;12:317–28. PubMed PMID: 25835095.
- Koboldt DC, Mihalic Mosher T, Kelly BJ, Sites E, Bartholomew D, Hickey SE, McBride K, Wilson RK, White P. A de novo nonsense mutation in ASXL3 shared by siblings with Bainbridge-Ropers syndrome. *Cold Spring Harb Mol Case Stud.* 2018;4:a002410. PubMed PMID: 29305346.
- Kuechler A, Czeschik JC, Graf E, Grasshoff U, Huffmeier U, Busa T, Beck-Woedl S, Faivre L, Riviere JB, Bader I, Koch J, Reis A, Hehr U, Rittinger O, Sperl W, Haack TB, Wieland T, Engels H, Prokisch H, Strom TM, Ludecke HJ, Wieczorek D. Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition. *Eur J Hum Genet.* 2017;25:183–191. PubMed PMID: 27901041.
- Micol JB, Abdel-Wahab O. The role of additional sex combs-like proteins in cancer. *Cold Spring Harb Perspect Med.* 2016;6:a026526. PubMed PMID: 27527698.



- Myers KA, White SM, Mohammed S, Metcalfe KA, Fry AE, Wraige E, Vasudevan PC, Balasubramanian M, Scheffer IE. Childhood-onset generalized epilepsy in Bainbridge-Ropers syndrome. *Epilepsy Res.* 2018a;140:166–70. PubMed PMID: 29367179.
- Myers KA, White SM, Mohammed S, Metcalfe KA, Fry AE, Wraige E, Vasudevan PC, Balasubramanian M, Scheffer IE. Corrigendum to "Childhood-onset generalized epilepsy in Bainbridge-Ropers syndrome". *Epilepsy Res.* 2018b;147:121. [Epilepsy Res. 2018;140:166-70]. PubMed PMID: 30104120.
- Qiao L, Liu Y, Ge J, Li T. Novel Nonsense Mutation in ASXL3 causing Bainbridge-Ropers Syndrome. *Indian Pediatr.* 2019;56:792–4. PubMed PMID: 31638014.
- Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, Vertino-Bell A, Smaoui N, Neidich J, Monaghan KG, Mcknight D, Bai R, Suchy S, Friedman B, Tahiliani J, Pineda-Alvarez D, Richard G, Brandt T, Haverfield E, Chung WK, Bale S. Clinical application of whole-exome sequencing across clinical indications. *Genet Med.* 2016;18:696–704. PubMed PMID: 26633542.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17:405–24. PubMed PMID: 25741868.
- Sahtoe DD, Van Dijk WJ, Ekkebus R, Ovaa H, Sixma TK. BAP1/ASXL1 recruitment and activation for H2A deubiquitination. *Nat Commun.* 2016;7:10292. PubMed PMID: 26739236.
- Schirwani S, Hauser N, Platt A, Punj S, Prescott K, Canham N, Mansour S, Balasubramanian M, et al. Mosaicism in ASXL3-related syndrome: Description of five patients from three families. *Eur J Med Genet.* 2020;6:103925. PubMed PMID: 32240826.
- Shashi V, Pena LD, Kim K, Burton B, Hempel M, Schoch K, Walkiewicz M, Mclaughlin HM, Cho M, Stong N, Hickey SE, Shuss CM, Undiagnosed Diseases N, Freemark MS, Bellet JS, Keels MA, Bonner MJ, El-Dairi M, Butler M, Kranz PG, Stumpel CT, Klinkenberg S, Oberndorff K, Alawi M, Santer R, Petrovski S, Kuismin O, Korpi-Heikkila S, Pietilainen O, Aarno P, Kurki MI, Hoischen A, Need AC, Goldstein DB, Kortum F. De Novo Truncating Variants in ASXL2 Are Associated with a Unique and Recognizable Clinical Phenotype. *Am J Hum Genet.* 2016;99:991–9. PubMed PMID: 27693232.
- Srivastava A, Ritesh KC, Tsan YC, Liao R, Su F, Cao X, Hannibal MC, Keegan CE, Chinnaiyan AM, Martin DM, Bielas SL. De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. *Hum Mol Genet.* 2016;25:597–608. PubMed PMID: 26647312.
- Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. *Hum Genet.* 2020;139:1197–207. PubMed PMID: 32596782.
- Verhoeven W, Egger J, Rakers E, Van Erkelens A, Pfundt R, Willemsen MH. Phenotypic characterization of an older adult male with late-onset epilepsy and a novel mutation in ASXL3 shows overlap with the associated Bainbridge-Ropers syndrome. *Neuropsychiatr Dis Treat.* 2018;14:867–70. PubMed PMID: 29628764.
- Wayhelova M, Oppelt J, Smetana J, Hladilkova E, Filkova H, Makaturova E, Nikolova P, Beharka R, Gaillyova R, Kuglik P. Novel de novo frameshift variant in the ASXL3 gene in a child with microcephaly and global developmental delay. *Mol Med Rep.* 2019;20:505–12. PubMed PMID: 31180560.
- Wei Z, Sun B, Wang ZP, et al. Whole-exome sequencing identifies novel recurrent somatic mutations in sporadic parathyroid adenomas. *Endocrinology.* 2018;159:3061–8. PubMed PMID: 29982334.
- Wright CF, Fitzgerald TW, Jones WD, Clayton S, Mcrae JE, Van Kogelenberg M, King DA, Ambridge K, Barrett DM, Bayzatinova T, Bevan AP, Bragin E, Chatzimichali EA, Gribble S, Jones P, Krishnappa N, Mason LE, Miller R, Morley KI, Parthiban V, Prigmore E, Rajan D, Sifrim A, Swaminathan GJ, Tivey AR, Middleton A, Parker M, Carter NP, Barrett JC, Hurles ME, Fitzpatrick DR, Firth HV, et al. Genetic diagnosis of

developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet*. 2015;385:1305–14. PubMed PMID: 25529582.

Zhang R, He XH, Lin HY, Yang XH. *Zhonghua Er Ke Za Zhi*. 2018;56:138–141. [Bainbridge-Ropers syndrome with ASXL3 gene variation in a child and literature review]. PubMed PMID: 29429203.

## License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: [admasst@uw.edu](mailto:admasst@uw.edu).